First Berlin Equity Research Initiates 'Buy' Rating for Medigene AG

On January 16, 2025, First Berlin Equity Research GmbH initiated coverage on Medigene AG with a 'Buy' recommendation and a target price of €3.80. The research, led by analyst Christian Orquera, marks a notable development for the German immuno-oncology company.

Medigene AG focuses on T cell receptor (TCR)-guided therapies, aiming to eliminate cancer cells without damaging healthy tissue. These therapies leverage unique proteins on T cells that recognize markers on cancer cells. Medigene's platform supports various therapeutic modalities, including partnerships that supplement its innovative approaches.

The company has formed strategic alliances with industry leaders such as BioNTech, Regeneron, and WuXi Biologics. A recent collaboration with WuXi paved the way for developing MDG 3010, targeting the KRAS G12V neoantigen in solid tumors.

Medigene plans to demonstrate proof-of-principle for MDG 3010 by the end of 2025. The outcome could lead to a licensing agreement, enhancing its market potential.